Derivation and Evaluation of Putative Adverse Outcome Pathways for Effects of Cycylooxygenase inhibitors on Reproductive Processes in Female Fish

Description

Fathead minnows (Pimephales promelas) were exposed to 100 ug/L indomethacin, 200 ug/L ibuprofen, or 20 ug/L celecoxib for 96 h. Effects on cycloxygenase enzyme activity in ovary, prostaglandin F2alpha concentrations in plasma, 17beta-estradiol concentrations in plasma, and vitellogenin concentrations in plasma were measured. Gene expression in ovary samples was evaluated using a 15,000 probe oligonucleotide microarray. Transcriptomics data (raw data and normalized) are available through the National Center for Biotechnology Information, Gene Expression Omnibus (GEO), accession number GSE72976. Metabolite profiles in liver tissue were measured by proton nuclear magnetic resonance. In addition to these data, the data set also contains identification of differentially expressed genes, pathway enrichment and gene set enrichment analyes, ToxCast data for indomethacin and celecoxib, chemical-gene interaction data derived from the Comparative Toxicogenomics database, and results from Level 1, Level 2, and Level 3 SeqAPASS analyses that examine conservation of target proteins across species (https://seqapass.epa.gov/seqapass/). This dataset is associated with the following publication: Martinovic-Weigelt, D., A. Mehinto, G. Ankley , J. Berninger, T. Collette , J. Davis , N. Denslow, E. Durhan, E. Eid, D. Ekman , K. Jensen , M. Kahl , C. LaLone , Q. Teng , and D. Villeneuve. Derivation and evaluation of putative adverse outcome pathways for the effects of cyclooxygenase inhibitors on reproductive processes in female fish. TOXICOLOGICAL SCIENCES. Society of Toxicology, 156(2): 344-361, (2017).

Resources

Name Format Description Link
53 9%20ORD-013745%20SeqAPASS%20level%202%2C%20cox2.csv https://pasteur.epa.gov/uploads/10.23719/1503124/9%20ORD-013745%20SeqAPASS%20level%202%2C%20cox2.csv
53 14%20ORD-013745%20COX%20Inhib_Metabolomics_PCA.xlsx https://pasteur.epa.gov/uploads/10.23719/1503124/14%20ORD-013745%20COX%20Inhib_Metabolomics_PCA.xlsx
53 8%20ORD-013745%20SeqAPASS%20level%202%2C%20cox1.csv https://pasteur.epa.gov/uploads/10.23719/1503124/8%20ORD-013745%20SeqAPASS%20level%202%2C%20cox1.csv
53 2%20ORD-013745%20Pathway%20enrichment%20and%20GSEA.xlsx https://pasteur.epa.gov/uploads/10.23719/1503124/2%20ORD-013745%20Pathway%20enrichment%20and%20GSEA.xlsx
53 4%20ORD-013745%20ToxCast%20data.xlsx https://pasteur.epa.gov/uploads/10.23719/1503124/4%20ORD-013745%20ToxCast%20data.xlsx
53 7%20ORD-013745%20SeqAPASS%20level%201%2C%20cox2.csv https://pasteur.epa.gov/uploads/10.23719/1503124/7%20ORD-013745%20SeqAPASS%20level%201%2C%20cox2.csv
0 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE72976
53 3%20ORD-013745%20Ingenuity%20Pathway%20Analyes.xlsx https://pasteur.epa.gov/uploads/10.23719/1503124/3%20ORD-013745%20Ingenuity%20Pathway%20Analyes.xlsx
53 13%20ORD-013745%20COX%20Inhib_Metabolomics_Diff%20Spec.xlsx https://pasteur.epa.gov/uploads/10.23719/1503124/13%20ORD-013745%20COX%20Inhib_Metabolomics_Diff%20Spec.xlsx
53 11%20ORD-013745%20SeqAPASS%20level%203%2C%20cox2.xlsx https://pasteur.epa.gov/uploads/10.23719/1503124/11%20ORD-013745%20SeqAPASS%20level%203%2C%20cox2.xlsx
53 1%20ORD-013745%20Differentially%20expressed%20genes.xlsx https://pasteur.epa.gov/uploads/10.23719/1503124/1%20ORD-013745%20Differentially%20expressed%20genes.xlsx
53 5%20ORD-013745%20CTD%20Chemical-gene%20interactions.xlsx https://pasteur.epa.gov/uploads/10.23719/1503124/5%20ORD-013745%20CTD%20Chemical-gene%20interactions.xlsx
53 10%20ORD-013745%20SeqAPASS%20level%203%2C%20cox1.xlsx https://pasteur.epa.gov/uploads/10.23719/1503124/10%20ORD-013745%20SeqAPASS%20level%203%2C%20cox1.xlsx
53 12%20ORD-013745%20MartinovicToxSCI_VTG_E2_COX_PGF.xlsx https://pasteur.epa.gov/uploads/10.23719/1503124/12%20ORD-013745%20MartinovicToxSCI_VTG_E2_COX_PGF.xlsx
53 6%20ORD-013745%20SeqAPASS%20level%201%2C%20cox1.csv https://pasteur.epa.gov/uploads/10.23719/1503124/6%20ORD-013745%20SeqAPASS%20level%201%2C%20cox1.csv

Tags

  • screening-and-prioritization
  • endocrine-disruption
  • ecotoxicology
  • adverse-outcome-pathway
  • aquatic-ecosystems

Topics

Categories